NASDAQ:OVID - Ovid Therapeutics Stock Price, Forecast & News

Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID."

Ovid Therapeutics Inc (NASDAQ:OVID) released its earnings results on Friday, November, 8th. The company reported ($0.43) EPS for the quarter, beating analysts' consensus estimates of ($0.45) by $0.02. View Ovid Therapeutics' Earnings History.

Ovid Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Ovid Therapeutics.

8 equities research analysts have issued 12-month price targets for Ovid Therapeutics' stock. Their forecasts range from $10.00 to $27.00. On average, they anticipate Ovid Therapeutics' stock price to reach $14.00 in the next year. This suggests a possible upside of 248.3% from the stock's current price. View Analyst Price Targets for Ovid Therapeutics.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ovid Therapeutics.

News articles about OVID stock have been trending very positive on Friday, InfoTrie reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Ovid Therapeutics earned a media sentiment score of 3.5 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Ovid Therapeutics.

Ovid Therapeutics saw a decline in short interest in the month of November. As of November 15th, there was short interest totalling 424,100 shares, a decline of 35.6% from the October 31st total of 659,000 shares. Based on an average daily volume of 610,800 shares, the short-interest ratio is presently 0.7 days. Approximately 1.8% of the company's shares are short sold. View Ovid Therapeutics' Current Options Chain.

Some companies that are related to Ovid Therapeutics include Revance Therapeutics (RVNC), Eagle Pharmaceuticals (EGRX), Aurinia Pharmaceuticals (AUPH), Akebia Therapeutics (AKBA), Kura Oncology (KURA), Omeros (OMER), ANI Pharmaceuticals (ANIP), Flexion Therapeutics (FLXN), Homology Medicines (FIXX), Synthorx (THOR), Collegium Pharmaceutical (COLL), Cara Therapeutics (CARA), TherapeuticsMD (TXMD), Axovant Sciences (AXON) and Phathom Pharmaceuticals (PHAT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ovid Therapeutics investors own include Corbus Pharmaceuticals (CRBP), Zynerba Pharmaceuticals (ZYNE), Amicus Therapeutics (FOLD), Anavex Life Sciences (AVXL), Sorrento Therapeutics (SRNE), Heron Therapeutics (HRTX), Marinus Pharmaceuticals (MRNS), Progenics Pharmaceuticals (PGNX), Verastem (VSTM) and AcelRx Pharmaceuticals (ACRX).

(OVID) raised $80 million in an initial public offering on Friday, May 5th 2017. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. Citigroup and Cowen and Company acted as the underwriters for the IPO and William Blair and JMP Securities were co-managers.

Ovid Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Granite Point Capital Management L.P. (0.90%), Redmile Group LLC (0.26%), Millennium Management LLC (0.21%), Virtu Financial LLC (0.05%) and Commonwealth Equity Services LLC (0.04%). Company insiders that own Ovid Therapeutics stock include Douglas E Williams, Jeremy M Levin, Karen Bernstein and Pharmaceutical Co Ltd Takeda. View Institutional Ownership Trends for Ovid Therapeutics.

OVID stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Redmile Group LLC and Granite Point Capital Management L.P.. View Insider Buying and Selling for Ovid Therapeutics.

OVID stock was acquired by a variety of institutional investors in the last quarter, including Virtu Financial LLC and Commonwealth Equity Services LLC. Company insiders that have bought Ovid Therapeutics stock in the last two years include Douglas E Williams, Jeremy M Levin, Karen Bernstein and Pharmaceutical Co Ltd Takeda. View Insider Buying and Selling for Ovid Therapeutics.

Shares of OVID can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of OVID stock can currently be purchased for approximately $4.02.

Ovid Therapeutics has a market capitalization of $192.22 million. The company earns $-51,980,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Ovid Therapeutics employs 55 workers across the globe.View Additional Information About Ovid Therapeutics.

The official website for Ovid Therapeutics is http://www.ovidrx.com/.

Ovid Therapeutics' mailing address is 1460 BROADWAY SUITE 15044, NEW YORK NY, 10036. The company can be reached via phone at 646-661-7661 or via email at [email protected]